Top

Reactions Weekly

Published in:

01-04-2024 | Erythropoietin | Case report

Daratumumab/erythropoietin/rituximab

Lack of efficacy

Published in: Reactions Weekly | Issue 1/2024

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Longval T. Efficacy and safety of Daratumumab for the treatment of ABO-incompatible Pure Red Cell aplasia after allogenic HSCT: report from SFGM-TC. Swiss Medical Weekly 153 (Suppl.): 22S abstr. 214, No. 11, Jan 2023. Available from: URL: https://dx.doi.org/10.57187/s.3469 [abstract]

Title: Daratumumab/erythropoietin/rituximab
Lack of efficacy
Publication date: 01-04-2024
Publisher: Springer International Publishing
Keywords: Erythropoietin
Erythropoietin
Epoetin alfa
Daratumumab
Rituximab
Rituximab
Erythrocyte Transfusion
Published in: Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-56795-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Daratumumab/erythropoietin/rituximab

Lack of efficacy

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Iodine-radioactive

Loperamide/Nintedanib

Cinacalcet

Tozinameran

Rituximab

Empagliflozin